Core Laboratories (NYSE:CLB – Get Rating)’s share price reached a new 52-week low during trading on Friday . The stock traded as low as $13.96 and last traded at $14.32, with a volume of 2854 shares changing hands. The stock had previously closed at $15.74.
Analysts Set New Price Targets
Several equities analysts have commented on the company. Stifel Nicolaus cut their price target on Core Laboratories from $26.00 to $20.00 in a report on Tuesday, July 26th. Morgan Stanley cut their price target on Core Laboratories from $22.00 to $20.00 and set an “equal weight” rating for the company in a report on Monday, August 1st.
Core Laboratories Stock Performance
The company has a market capitalization of $667.15 million, a P/E ratio of 75.58, a price-to-earnings-growth ratio of 0.72 and a beta of 2.59. The firm has a 50 day moving average price of $17.04 and a two-hundred day moving average price of $23.29. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.53 and a current ratio of 2.08.
Core Laboratories Cuts Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, August 29th. Stockholders of record on Monday, August 8th were paid a $0.01 dividend. The ex-dividend date was Friday, August 5th. This represents a $0.04 annualized dividend and a dividend yield of 0.28%. Core Laboratories’s dividend payout ratio is currently 21.05%.
Institutional Investors Weigh In On Core Laboratories
Large investors have recently modified their holdings of the stock. Boston Trust Walden Corp bought a new stake in Core Laboratories during the 2nd quarter worth approximately $39,492,000. Marshall Wace LLP grew its position in Core Laboratories by 382.2% during the 4th quarter. Marshall Wace LLP now owns 835,491 shares of the oil and gas company’s stock worth $18,638,000 after acquiring an additional 662,216 shares during the last quarter. Congress Asset Management Co. MA bought a new stake in Core Laboratories during the 1st quarter worth approximately $13,499,000. Ariel Investments LLC grew its position in Core Laboratories by 5.1% during the 1st quarter. Ariel Investments LLC now owns 8,198,544 shares of the oil and gas company’s stock worth $259,320,000 after acquiring an additional 394,237 shares during the last quarter. Finally, Van ECK Associates Corp grew its position in Core Laboratories by 21.5% during the 1st quarter. Van ECK Associates Corp now owns 2,098,713 shares of the oil and gas company’s stock worth $66,382,000 after acquiring an additional 370,891 shares during the last quarter. 98.22% of the stock is currently owned by institutional investors.
About Core Laboratories
Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, reservoir fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.
- Get a free copy of the StockNews.com research report on Core Laboratories (CLB)
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- What Steelcase’s Earnings Say About the Return to the Office?
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.